SCHEMBL1002452

SCHEMBL1002452

CC(C)Oc1ccc(NC(=O)c2cccc(S(=O)(=O)C3CCCCC3)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.48
KDM4E B2RXH2 3/20 0.48
MAPT P10636 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
HSD17B10 Q99714 3/20 0.47
TDP1 Q9NUW8 1/20 0.47
NPC1 O15118 1/20 0.47
HPGD P15428 1/20 0.47
RAB9A P51151 1/20 0.47
ALDH1A1 P00352 4/20 0.47
USP2 O75604 1/20 0.47
ALOX15 P16050 1/20 0.47
LMNA P02545 4/20 0.46
TP53 P04637 2/20 0.46
MAPK1 P28482 2/20 0.46
HTR2B P41595 1/20 0.46
KAT6A Q92794 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1001949 0.89 MEN1 (0.67) KMT2AMEN1HTTSMN1; SMN2KDM4E
SCHEMBL28004741 0.87 SMN1; SMN2 (0.55) KMT2AMEN1SMN1; SMN2KDM4EMAPT
SCHEMBL16903002 0.84 SMN1; SMN2 (0.62) KMT2AMEN1SMN1; SMN2MAPTL3MBTL1
SCHEMBL17128989 0.83 HTR2B (0.63) KMT2AMEN1SMN1; SMN2KDM4EMAPT
SCHEMBL1002080 0.81 HTR2B (0.53) KMT2AMEN1HTTSMN1; SMN2KDM4E
SCHEMBL1001582 0.81 KMT2A (0.80) KMT2AMEN1SMN1; SMN2KDM4EMAPT
SCHEMBL1001981 0.81 SMN1; SMN2 (0.54) KMT2AMEN1HTTSMN1; SMN2KDM4E
SCHEMBL1001481 0.79 KMT2A (0.56) KMT2AMEN1HTTSMN1; SMN2MAPT
SCHEMBL1001743 0.79 KMT2A (0.56) KMT2AMEN1HTTSMN1; SMN2MAPT
SCHEMBL1000747 0.78 KMT2A (0.64) KMT2AMEN1HTTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280001-B1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD KK (JP) 2014-10-15 EP claimed
EP-2280001-B1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD KK (JP) 2014-10-15 EP disclosed
US-8420823-B2 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient MSD K.K. (JP) 2013-04-16 US disclosed
EP-2280001-A1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT Banyu Pharmaceutical Co., Ltd. (JP) 2011-02-02 EP disclosed
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD K.K. (JP) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT ELOVL1, ELOVL6, ELOVL3 KMT2A 473/4885MEN1 4600/4885HTT 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.